

F. No. ND/MA/24/000147
Government of India
Directorate General of Health Services
Central Drugs Standard Control Organization
(New Drugs Division)

FDA Bhawan, Kotla Road,
New Delhi-11 0002

To

M/s MSN Laboratories Private Limited,
MSN HOUSE - C24, INDUSTRIAL ESTATE,
SANATHNAGAR, Hyderabad (India) - 500018

Subject: Grant of permission to conduct Phase-III Clinical trial of drug Vibegron Tablets 75mg vide protocol entitled "A phase-III, randomized, open label, active controlled, multicenter study to evaluate the safety and efficacy of Vibegron 75 mg tablet, in comparison with Mirabegron ER 25mg/50mg Tablet in Patients with Overactive Bladder (OAB)" Protocol No. 003/VIB/MSN/2024, Version 2.0 Dated 12/JULY/2025.- regarding.

Sir,

With reference to your application no. **ND/CT21/FF/2024/46041**, dated **25.10.2024**, please find enclosed herewith the permission in **Form CT-06**, vide No. **ND/CT/34 /2025** to conduct the subject mentioned clinical trial under the provisions of New Drugs and Clinical Trial Rules, 2019.

This permission is subject to the conditions, as mentioned below.

Yours faithfully

RAJEEV SINGH Digitally signed by RAJEEV
SINGH RAGHUVANSHI
RAGHUVANSHI Date: 2025.10.22 15:08:44
+05'30'
(Dr. Rajeev Singhi Raghuvanshi)
Drugs Controller General (India)

Conditions of permission

- (i) Clinical trial at each site shall be initiated after approval of the clinical trial protocol and other related documents by the Ethics Committee of that site, registered with the Central Licencing Authority under Rule 8;
- (ii) Where a clinical trial site does not have its own Ethics Committee, clinical trial at that site may be initiated after obtaining approval of the protocol from the Ethics

Committee of another trial site; or an independent Ethics Committee for clinical trial constituted in accordance with the provisions of Rule 7:

Provided that the approving Ethics Committee for clinical trial shall in such case be responsible for the study at the trial site or the centre, as the case may be:

Provided further that the approving Ethics Committee and the clinical trial site or the bioavailability and bioequivalence centre, as the case may be, shall be located within the same city or within a radius of 50 kms of the clinical trial site;

- (iii) In case an ethics committee of a clinical trial site rejects the approval of the protocol, the details of the same shall be submitted to the Central Licensing Authority prior to seeking approval of another Ethics Committee for the protocol for conduct of the clinical trial at the same site;
- (iv) The Central Licencing Authority shall be informed about the approval granted by the Ethics Committee within a period of fifteen working days of the grant of such approval;
- (v) Clinical trial shall be registered with the Clinical Trial Registry of India maintained by the Indian Council of Medical Research before enrolling the first subject for the trial;
- (vi) Clinical trial shall be conducted in accordance with the approved clinical trial protocol and other related documents and as per requirements of Good Clinical Practices Guidelines and the provisions of these rules;
- (vii) Status of enrolment of the trial subjects shall be submitted to the Central Licencing Authority on quarterly basis or as appropriate as per the duration of treatment in accordance with the approved clinical trial protocol, whichever is earlier;
- (viii) Six monthly status report of each clinical trial, as to whether it is ongoing, completed or terminated, shall be submitted to the Central Licencing Authority;
- (ix) In case of termination of any clinical trial the detailed reasons for such termination shall be communicated to the Central Licencing Authority within thirty working days of such termination;
- (x) Any report of serious adverse event occurring during clinical trial to a subject of clinical trial, shall, after due analysis, be forwarded to the Central Licencing Authority, the chairperson of the Ethics Committee and the institute where the trial has been conducted within fourteen days of its occurrence as per Table 5 of the Third Schedule and in compliance with the procedures as specified in Chapter VI of the New Drugs and Clinical Trials Rules, 2019;
- (xi) In case of injury during clinical trial to the subject of such trial, complete medical management and compensation shall be provided in accordance with the Chapter VI of the said Rules and details of compensation provided in such cases shall be intimated to the Central Licencing Authority within thirty working days of the receipt of order issued by Central Licencing Authority in *accordance* with the provisions of the said Chapter;
- (xii) In case of clinical trial related death or permanent disability of any subject of such trial during the trial, compensation shall be provided in accordance with the Chapter VI and details of compensation provided in such cases shall be intimated to the Central Licencing Authority within thirty working days of receipt of the order issued by the Central Licencing Authority in accordance with the provisions of the said Chapter;

- (xiii) The premises of the sponsor including his representatives and clinical trial sites, shall be open for inspection by officers of the Central Licencing Authority who may be accompanied by officers of the State Licencing Authority or outside experts as authorized by the Central Licencing Authority, to verify compliance of the requirements of these rules and Good Clinical Practices Guidelines, to inspect, search and seize any record, result, document, investigational product, related to clinical trial and furnish reply to query raised by the said officer in relation to clinical trial;
- (xiv) Where the New Drug or Investigational New Drug is found to be useful in clinical development, the sponsor shall submit an application to the Central Licencing Authority for permission to import or manufacture for sale or for distribution of new drug in India, in accordance with Chapter X of these rules, unless otherwise justified;
- (xv) The Laboratory owned by any person or a company or any other legal entity and utilized by that person to whom permission for clinical trial has been granted used for research and development, shall be deemed to be registered with the Central Licencing Authority and may be used for test or analysis of any drug for and on behalf of Central Licencing Authority;
- (xvi) The Central Licencing Authority may, if considered necessary, impose any other condition in writing with justification, in respect of specific clinical trials, regarding the objective, design, subject population, subject eligibility, assessment, conduct and treatment of such specific clinical trial;
- (xvii) The sponsor and the investigator shall maintain the data integrity of the data generated during clinical trial.
- (xviii) Informed Consent Documents (ICD) viz. Patient Information Sheet (PIS) and Informed Consent Form (ICF) complete in all respect & must be got approved from the respective Ethics committee and submitted to CDSCO before enrolling first subject at the respective site.
- (xix) The Informed Consent Document including ICF and Patient Information Sheet should clearly mention in understandable language about the details of the drug therapy that the patient may or may not receive.
- (xx) **Patients with refractory overactive bladder (OAB) should be excluded from the trial.**

FORM CT-06

(See rules 22, 25, 26, 29 and 30)

PERMISSION TO CONDUCT CLINICAL TRIAL OF NEW DRUG OR INVESTIGATIONAL NEW DRUG**CT Permission No: ND/CT/34/2025**

The Central Licensing Authority hereby permits, **M/s MSN Laboratories Private Limited ,MSN HOUSE - C24, INDUSTRIAL ESTATE, SANATH NAGAR, Hyderabad (India) - 500018 Telephone No.: 04030438712,8664,8302,8604 FAX: 04030438798 E-Mail : krreddy@msnlabs.com** to conduct clinical trial of the new drug as per **Protocol Number: 003/VIB/MSN/2024,, Version No.:2.0, dated: 12/JULY/2025** in the below mentioned clinical trials sites.

2. Details of new drug or investigational new drug and clinical trial site:

Names of the new drug or investigational new drug:	Vibegron Tablets 75 mg	
Therapeutic class:	beta-3 adrenergic agonist	
Dosage form:	Tablets	
Composition:	Each Tablet contains Vibegron.....75mg	
Indications:	Indicated for the treatment of overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency, and urinary frequency in adults.	
Details of clinical trial sites-		
Sr. No.	Name of Principal Investigator & Trial Sites	Ethics Committee Name/ Registration Number
1.	Dr. Sourav Sarkar , MBBS, MS, College of Medicine and JNM Hospital, Department of Obstetrics and Gynecology Kalyani, Nadia, West Bengal 741235	ECR/674/Inst/WB/2014/ RR-21 I E C, College of Medicine JNM Hospital, West Bengal University Of Health Sciences, Kalyani Nadia Kolkata West Bengal - 741235 India
2.	Dr. Prem Mohan Jha , MBBS, M.D, D.M, DrNB(Nephro), Gangasheel Advanced Medical Research Institute C- 17, Deen Dayal Puram, Bareilly, Uttar Pradesh 243122	ECR/1319/Inst/UP/2019/RR-24 Institutional Ethics Committee, Gangasheel Advanced Medical Research Institute C-17, Deen Dayal Puram, Near OBC Bank, Bareilly, Uttar Pradesh - 243001, India
3.	Dr. Vinay Kumar , MBBS, MS (Surgery), MCH (Urology), Department Of Surgery, GSVM Medical College, Kanpur, UP-208002	ECR/680/Inst/UP/2014/ RR-20 Ethics Committee Gsvm Medical College Kanpur, Swaroop Nagar Kanpur, Kanpur Nagar Uttar Pradesh - 208002 India
4.	Dr. Suraj Kumar Pattanayak , MBBS, MS (Surgery), Government Medical College & Government General Hospital,	ECR/2088/Inst/AP/2025 Institutional Ethics Committee, Government General Hospital, Srikakulam, Shanti Nagar Colony,

	Srikakulam, AP- 532001	Balaga Srikakulam, Andhra Pradesh - 532001 India
5.	Dr. Mane Narsing Laxman , MBBS, MS, MCH (Urology), Supe Heart & Diabetes Hospital & Research Centre, Opp. Adhar Ashram, Near Rungta School, Gharpure Ghat, Ashok Stambh, Nashik, Maharashtra – 422002	ECR/272/Inst/MH/2013/ RR-24 Supe Hospital Ethics Committee Supe Heart Diabetes Hospital and Research Centre Opp. Adharashram, Gharpure ghat Near Rungtha school, Ashok Stambha Nashik Nashik Maharashtra - 422002 India
6.	Dr. Atul Singal , MBBS, MS, M.ch (Urology), Life Care Hospital, Lekha Nagar, Mumbai -Agra highway, Nashik- 422009, Maharashtra, India	ECR/251/Inst/Maha/201 3/RR-24 Muktai Hospital Institutional Ethics Committee, Muktai Hospital, Plot no.11, Shivaji Nagar, Nashik-Pune Road, Nashik- 422006, Maharashtra, India.
7.	Dr. Tushar Narkhede , MBBS, MS, M.ch (Urology), Omkar ENT Hospital, SK Empire, Near Ved Mandir, Micro Circle, Trambak Road, Nashik- 422002	ECR/251/Inst/Maha/201 3/RR-24 Muktai Hospital Institutional Ethics Committee, Muktai Hospital, Plot no.11, Shivaji Nagar, Nashik-Pune Road, Nashik- 422006, Maharashtra, India.
8.	Dr. Sunirmal Choudhary , MBBS, DA, MS, M.ch (Urology), Medical college Kolkata, Department of Urology, Medical College Kolkata 88, College street, Kolkata, West Bengal-700073, India	ECR/287/Inst/WB/2013/ RR-24 Institutional Ethics Committee for Human Research, Medical College, Kolkata 88, College Street Kolkata, West Bengal - 700073 India

3. This permission is subject to the conditions prescribed in part A of Chapter V of the New Drugs and Clinical Trials Rules, 2019 under the Drugs and Cosmetics Act, 1940.

RAJEEV SINGH
RAGHUVANSHI
 (Dr. Rajeev Singh Raghuvanshi)
Central Licensing Authority

Digitally signed by RAJEEV SINGH RAGHUVANSHI
 Date: 2025.10.22 15:09:06
 05:30

New Delhi